Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Davide Melisi, Do‐Youn Oh, Antoine Hollebecque, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e002068-e002068
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Overcoming TGFβ-mediated immune evasion in cancer
Daniele V. F. Tauriello, Elena Sancho, Eduard Batlle
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 25-44
Open Access | Times Cited: 223
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Zengli Fang, Qingcai Meng, Jin Xu, et al.
Cancer Communications (2022) Vol. 43, Iss. 1, pp. 3-41
Open Access | Times Cited: 133
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
James L. Gulley, Jeffrey Schlom, Mary Helen Barcellos‐Hoff, et al.
Molecular Oncology (2021) Vol. 16, Iss. 11, pp. 2117-2134
Open Access | Times Cited: 111
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Zhenduo Shi, Kun Pang, Zhuo‐Xun Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 102
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
Lisa H. Butterfield, Yana G. Najjar
Nature reviews. Immunology (2023) Vol. 24, Iss. 6, pp. 399-416
Closed Access | Times Cited: 100
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Tianyi Zhang, Yanxian Ren, Pengfei Yang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 10
Open Access | Times Cited: 96
Targeting inflammation as cancer therapy
Manni Wang, Siyuan Chen, Xuemei He, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 32
Engineering and Targeting Neutrophils for Cancer Therapy
Jiahui Zhang, Jianmei Gu, Xu Wang, et al.
Advanced Materials (2024) Vol. 36, Iss. 19
Open Access | Times Cited: 30
Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Wenyu Luo, Ti Wen, Xiujuan Qu
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 24
Neutrophils in cancer: dual roles through intercellular interactions
Xinyu Yu, Changhui Li, Zijin Wang, et al.
Oncogene (2024)
Closed Access | Times Cited: 24
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
David Danielpour
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 533-533
Open Access | Times Cited: 21
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
TGF-beta signal transduction: biology, function and therapy for diseases
Yan Tie, Fan Tang, Dandan Peng, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 68
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Lingyue Liu, Xing Huang, Fukang Shi, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 59
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bruno Bockorny, Joseph E. Grossman, Manuel Hidalgo
Clinical Cancer Research (2022) Vol. 28, Iss. 21, pp. 4606-4617
Closed Access | Times Cited: 57
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective
Briana G. Nixon, Shengyu Gao, Xinxin Wang, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 6, pp. 346-362
Open Access | Times Cited: 56
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 54
Cancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets
Shinelle Menezes, Mohamed Hazem Okail, Siti Munira Abd Jalil, et al.
The Journal of Pathology (2022) Vol. 257, Iss. 4, pp. 526-544
Open Access | Times Cited: 52
TGF-β signaling networks in the tumor microenvironment
Max Kam‐Kwan Chan, Jeff Yat‐Fai Chung, Philip Chiu‐Tsun Tang, et al.
Cancer Letters (2022) Vol. 550, pp. 215925-215925
Closed Access | Times Cited: 48
The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial
Anastasia E. Metropulos, Hidayatullah G. Munshi, Daniel R. Principe
EBioMedicine (2022) Vol. 86, pp. 104380-104380
Open Access | Times Cited: 48
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe, Suneel D. Kamath, Murray Korc, et al.
Pharmacology & Therapeutics (2022) Vol. 236, pp. 108111-108111
Open Access | Times Cited: 45
Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy
Hans Raskov, Adile Orhan, Shruti Gaggar, et al.
Oncogenesis (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma
Shailendra K. Gautam, Surinder K. Batra, Maneesh Jain
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 39
Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies
Ibraheem Nasir, Conor McGuinness, Ashleigh R. Poh, et al.
Trends in Immunology (2023) Vol. 44, Iss. 12, pp. 971-985
Open Access | Times Cited: 38
Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy
Qiang Li, Megan T. Hoffman, Lestat R. Ali, et al.
Gastroenterology (2023) Vol. 165, Iss. 4, pp. 874-890.e10
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top